Showing 2640 results
- Media Release /Net sales grew 2% (cc, -1% USD), as growth drivers more than offset Gleevec/Glivec impact Cosentyx (USD 410 million, +136% cc) showing strong growth in all three indications Entresto (USD 84…
- Media Release /Chiffre d'affaires net en hausse de 2% (tcc, -1% en USD), car les moteurs de croissance ont plus que compensé l'impact de Gleevec/Glivec Cosentyx (USD 410 millions, +136% tcc):…
- Media Release /Chiffre d'affaires net en hausse de 1% (tcc[1]), les produits de croissance ayant compensé l'impact du générique de Gleevec Les produits de croissance[2] ont progressé de 24% (en USD) à USD 3,9…
- Media Release /Everolimus is the first adjunctive therapy shown in a prospective randomized Phase III study to achieve clinically significant seizure control in TSC patients[1] Seizures are the most…
- Media Release /Sandoz' epoetin alfa product offering has already generated more than 400,000[1] patient years of experience worldwide EC approval expands Sandoz biosimilar offering to the healthcare community…
- Media Release /EU approval of Revolade expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have not responded to other therapies Two formulations approved: once-daily…
- Media Release /New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless of prior heart…
- Media Release /Updated segment financials reflect transfer of Ophthalmic Pharmaceuticals franchise from Alcon to Pharmaceuticals, and 19 mature products from Pharmaceuticals to Sandoz, as outlined in Q4 and FY…
- Media Release /Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical dataBreast and gastric cancers are among most common types of cancer, accounting together for nearly half…
- Media Release /New data at AAD 2016 shows Cosentyx® is significantly more efficacious than Stelara in sustaining skin clearance (PASI 90 to PASI 100) at 52 weeks[1] Cosentyx delivered and sustained skin…
Pagination
- ‹ Previous page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- …
- 264
- › Next page